To craft an unbeatable prosecution strategy, patent attorneys should rely on the multi-dimensional analysis of an examiner’s data, rather than just summary metrics.

To succeed in any industry, a certain amount of foresight and planning is key. For patent attorneys, identifying and taking action on high-cost prosecution can lessen the usual timeline and save money in the long term.

Patent prosecution is expensive and complex. And often, each individual practitioner has their own unique approach to reach that all-important NOA. But inconsistent practices and reliance solely on past experience can lead to inflated costs.

United Technologies, an American multinational conglomerate, recently agreed to combine its aerospace business with military contractor Raytheon, creating a new manufacturing giant in the aerospace and defense sectors. Under the new name of Raytheon Technologies, the merged company would have about $74 billion in expected sales for 2019. 

Sprint and T-Mobile recently announced that they had reached a deal to merge, promising to “be a force for positive change in the U.S. wireless, video, and broadband industries.” Combining the country’s third and fourth largest mobile service providers would be one of the most significant consolidations in the American wireless market in years.

We’ve all been there. Prosecution is taking longer than expected. You’re facing one rejection after another. And your client is starting to question whether this patent is worth pursuing.

This precarious position is where Jonathan Miller of Nicholson De Vos Webster & Elliott LLP found himself during a recent prosecution.

Thanks to Juristat patent analytics, practitioners can now leverage data to make strategic decisions throughout the patent prosecution process.

Watch our latest video to learn how firms and in-house teams can shape strategy with big data during all parts of the prosecution process.

Due to inconsistent interpretation, preparing for and responding to Alice rejections has become one of the most stressful aspects of patent prosecution. Rejections citing Alice have multiplied exponentially since the initial decision on June 19, 2014, and they now account for more than 60% of §101 rejections and more than 8% of all rejections, as of our latest analysis.

Two of the biggest pharmaceutical companies are joining forces in a blockbuster merger. Bristol-Myers Squibb is buying Celgene in a cash and stock deal valued at about $74 billion.

If you were following patent and innovation news in 2018, it was hard to avoid mentions of 3D printing.